Amgen (NQ:AMGN)

349.82 -1.20 (-0.34%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9

...

65 66 Next >

Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment

Today 10:04 EDT

THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its...

Via MarketMinute

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

Today 9:35 EDT

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data

April 09, 2026

In a major victory for its rare disease portfolio, Amgen (NASDAQ: AMGN) announced positive topline results on April 6, 2026, from its pivotal Phase 3 clinical trial evaluating a subcutaneous (SC)...

Via MarketMinute

Topics Intellectual Property

The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss

April 08, 2026

In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the...

Via MarketMinute

Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing Sector ↗

April 07, 2026

Robert Half provides staffing and consulting services to global clients across accounting, finance, IT, legal, and creative sectors.

Via The Motley Fool

Topics Regulatory Compliance

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

April 03, 2026

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...

Via MarketMinute

Topics Intellectual Property

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Topics Economy Intellectual Property World Trade

2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory ↗

April 02, 2026

Dividend payers might become more popular if the recent volatility continues. These two stocks are great picks to weather the storm.

Via The Motley Fool

Topics Economy Retirement Stocks

Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones

April 02, 2026

The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that...

Via MarketMinute

Topics Intellectual Property

Dow, S&P 500, Nasdaq: From Morning Meltdown to Midday "Meh" ↗

April 02, 2026

Markets opened lower on Iran fears and a Tesla stumble, but bounced back. Here's what investors need to know about Thursday's volatile session.

Via The Motley Fool

Topics Government Stocks World Trade

The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)

April 02, 2026

As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...

Via MarketMinute

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗

March 30, 2026

The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks.

Via The Motley Fool

Topics ETFs Stocks

Institutional Titans Bet Big on Amgen as Dividend Yield Hits 2.9% Benchmark

March 23, 2026

In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026....

Via MarketMinute

Topics ETFs Earnings

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

Anthropic Is Worth $380 Billion: This Little-Known ETF Could Let You Own a Piece Before It IPOs ↗

March 19, 2026

Anthropic recently closed a $30 billion Series G funding round valuing the company at $380 billion.

Via The Motley Fool

Topics Artificial Intelligence ETFs

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report ↗

March 16, 2026

Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs.

Via Benzinga

1 ETF That Could Turn $100 Per Month Into $67,380 ↗

March 15, 2026

How does solid growth -- plus a 3.3% dividend yield sound?

Via The Motley Fool

Topics ETFs Economy World Trade

2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

March 13, 2026

Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that mos...

Via StockStory

Topics Energy

Rapid Micro (RPID) Earnings Call Transcript ↗

March 12, 2026

Rapid Micro (RPID) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

March 08, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (NASDAQ:AMGN) and its p...

Via StockStory

Topics Artificial Intelligence

Better Weight Loss Stock: Novo Nordisk Vs. Amgen ↗

March 08, 2026

They may appeal to different kinds of investors.

Via The Motley Fool

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

Via Stocktwits

Topics Artificial Intelligence

2 Profitable Stocks with Solid Fundamentals and 1 Facing Headwinds

March 02, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

A Couple's Financial Manifesto, Revisited ↗

March 02, 2026

There's nothing more romantic than talking about money with your partner. Right?

Via The Motley Fool

Topics Stocks

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

Via MarketMinute

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Via MarketMinute

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

Via MarketMinute

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

65 66 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.